What is IMV Inc. (IMVIQ)?

IMV Inc. (IMVIQ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IMVIQ?

The current price of IMVIQ is $0.00. Prices are updated in real time on Stocks360.

What is IMVIQ's price-to-earnings (PE) ratio?

IMVIQ's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is IMVIQ's market capitalization?

IMVIQ's market capitalization is $117.00, placing it in the small-cap tier.

IMV Inc. (IMVIQ)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$117.00

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.19

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $1.00

Avg Volume

N/A

Volume

2.00K

IMV Inc. (IMVIQ) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $117.00. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 16, 2023

EPS $-0.96 vs est. $-0.92

Missed by $0.04

Proprietary Signals

Signal snapshot temporarily unavailable.

About IMV Inc.

IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase. It leverages its proprietary DPX immune-modulating technology platform to create a range of therapeutic candidates aimed at both solid and blood-related cancers. Its primary investigational therapy, maveropepimut-S, is an immunotherapy built on the DPX platform, designed to target cells that express survivin. This compound is currently undergoing Phase II clinical evaluations for conditions such as diffuse large B-cell lymphoma, ovarian cancer, as well as solid tumors of the bladder, liver, and those exhibiting high microsatellite instability (MSI-H). Additionally, maveropepimut-S is in Phase I trials for breast cancer. Other developments include DPX-SurMAGE, which is in Phase I trials for bladder cancer, along with candidates like DPX-COVID-19 and DPX-RSV, which are being explored for infectious diseases. Previously known as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its headquarters in Dartmouth, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	-0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	-0.20×
EV / Sales	0.00×
Earnings Yield	-45533894.53%
Free Cash Flow Yield	-29461538.46%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.67M
Net Income (TTM)	-$53.27M
Free Cash Flow (TTM)	-$34.47M
Net Debt	$7.67M
Working Capital	$18.17M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-508.58%
Return on Invested Capital	-177.14%